Andrew Ishizuka, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria Vaccines | 7 | 2024 | 165 | 1.220 |
Why?
|
| Antibodies, Protozoan | 5 | 2024 | 251 | 0.870 |
Why?
|
| Malaria, Falciparum | 7 | 2024 | 1075 | 0.720 |
Why?
|
| Plasmodium falciparum | 7 | 2024 | 1739 | 0.630 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 4652 | 0.550 |
Why?
|
| Parasitemia | 1 | 2016 | 166 | 0.500 |
Why?
|
| Cancer Vaccines | 4 | 2024 | 1042 | 0.460 |
Why?
|
| Sporozoites | 5 | 2018 | 83 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 5 | 2023 | 996 | 0.380 |
Why?
|
| Vaccines, Virus-Like Particle | 2 | 2024 | 44 | 0.350 |
Why?
|
| Protozoan Proteins | 3 | 2024 | 843 | 0.330 |
Why?
|
| Vaccines, Attenuated | 3 | 2019 | 314 | 0.290 |
Why?
|
| Oncolytic Virotherapy | 2 | 2024 | 520 | 0.260 |
Why?
|
| Antigens, Neoplasm | 3 | 2022 | 1998 | 0.230 |
Why?
|
| Vaccination | 6 | 2023 | 3434 | 0.220 |
Why?
|
| Toll-Like Receptor 8 | 2 | 2020 | 98 | 0.190 |
Why?
|
| Plasmodium yoelii | 2 | 2018 | 41 | 0.190 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2020 | 169 | 0.180 |
Why?
|
| Liver | 1 | 2016 | 7571 | 0.170 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2020 | 175 | 0.170 |
Why?
|
| Bystander Effect | 1 | 2019 | 89 | 0.160 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2018 | 54 | 0.150 |
Why?
|
| RNA, Protozoan | 1 | 2018 | 46 | 0.150 |
Why?
|
| Therapies, Investigational | 1 | 2019 | 110 | 0.150 |
Why?
|
| Micelles | 1 | 2019 | 190 | 0.150 |
Why?
|
| Melanoma, Experimental | 1 | 2020 | 557 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 2571 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 2019 | 743 | 0.110 |
Why?
|
| Antigens | 1 | 2019 | 1441 | 0.110 |
Why?
|
| Immunotherapy | 3 | 2024 | 4747 | 0.110 |
Why?
|
| Macaca mulatta | 2 | 2018 | 2341 | 0.100 |
Why?
|
| Capsid Proteins | 1 | 2016 | 468 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 582 | 0.100 |
Why?
|
| Nanoparticles | 2 | 2020 | 1966 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2016 | 995 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2019 | 3158 | 0.090 |
Why?
|
| Immunization | 3 | 2019 | 1218 | 0.080 |
Why?
|
| Mice | 12 | 2024 | 81889 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3944 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2024 | 4924 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3804 | 0.080 |
Why?
|
| Antigens, Protozoan | 2 | 2024 | 315 | 0.080 |
Why?
|
| Oncolytic Viruses | 2 | 2024 | 344 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 5503 | 0.070 |
Why?
|
| Animals | 13 | 2024 | 168930 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 2010 | 0.070 |
Why?
|
| Vaccines | 1 | 2015 | 842 | 0.070 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 10264 | 0.070 |
Why?
|
| Genetic Vectors | 3 | 2023 | 3401 | 0.070 |
Why?
|
| Adaptive Immunity | 2 | 2023 | 734 | 0.060 |
Why?
|
| Melanoma | 1 | 2024 | 5700 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4559 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5329 | 0.060 |
Why?
|
| Peptides | 1 | 2016 | 4344 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 22352 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2024 | 6222 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 17088 | 0.050 |
Why?
|
| Immunologic Memory | 2 | 2019 | 1377 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2024 | 805 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2024 | 827 | 0.040 |
Why?
|
| Brefeldin A | 1 | 2019 | 68 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 334 | 0.040 |
Why?
|
| Young Adult | 4 | 2018 | 59939 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 9101 | 0.040 |
Why?
|
| Hydrodynamics | 1 | 2019 | 163 | 0.040 |
Why?
|
| Human Experimentation | 1 | 2018 | 125 | 0.040 |
Why?
|
| Female | 11 | 2024 | 396520 | 0.040 |
Why?
|
| Primates | 1 | 2020 | 519 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 3607 | 0.030 |
Why?
|
| Vaccinia virus | 1 | 2017 | 328 | 0.030 |
Why?
|
| Chloroquine | 1 | 2017 | 276 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1250 | 0.030 |
Why?
|
| Vaccines, DNA | 1 | 2016 | 279 | 0.030 |
Why?
|
| Humans | 13 | 2024 | 766766 | 0.030 |
Why?
|
| Adult | 6 | 2019 | 223307 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7438 | 0.030 |
Why?
|
| Adolescent | 3 | 2017 | 88904 | 0.030 |
Why?
|
| Tanzania | 1 | 2018 | 1406 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2018 | 12430 | 0.030 |
Why?
|
| Capsid | 1 | 2016 | 435 | 0.030 |
Why?
|
| Spleen | 1 | 2019 | 2295 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 8540 | 0.030 |
Why?
|
| Bacteriophages | 1 | 2016 | 382 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 1852 | 0.020 |
Why?
|
| Epitopes | 1 | 2017 | 2526 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2015 | 702 | 0.020 |
Why?
|
| Middle Aged | 4 | 2017 | 223257 | 0.020 |
Why?
|
| Malaria | 1 | 2019 | 1246 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2020 | 2747 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 3077 | 0.020 |
Why?
|
| Male | 5 | 2018 | 364142 | 0.020 |
Why?
|
| Rats | 1 | 2024 | 23717 | 0.020 |
Why?
|
| Protein Binding | 1 | 2019 | 9320 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15563 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2016 | 4211 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2019 | 18984 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16724 | 0.010 |
Why?
|
| Mutation | 1 | 2024 | 30213 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23619 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40149 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 65273 | 0.010 |
Why?
|
| Child | 1 | 2019 | 80668 | 0.010 |
Why?
|